Myriad Genetics increased its 2026 revenue forecast midpoint to $785 million, citing higher revenue per test that offsets expected softness in its Prenatal Health segment. The company attributes reimbursement challenges mainly to more zero-pay outcomes and denials, not contract or policy changes. Following its agreement to sell the Prenatal Health testing business to Labcorp, Myriad expects revenue growth to improve by over 1 percentage point and gross margin by more than 5 points post-sale. The company also anticipates significant profitability gains in 2027, supported by process improvements and AI-enhanced workflows.
Myriad Genetics' updated 2026 revenue outlook provides context for market activity today. For readers following broad cryptocurrency trends, here is Pluang's market snapshot as of Nov 07, 2026 08:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 37 rose and 12 fell. Notable movers include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, BAL (Balancer) up 11.14% at Rp16.297 with a typical hold time of 85 days, and EOS (EOS.IO) up 8.13% at Rp12.649 with a typical hold time of 87 days.
Bitcoin fell to $75,568 and Ether dropped to $2,237, triggering forced liquidations of leveraged positions totaling about $1.033 billion over 24 hours. Most liquidations were long positions, indicating many traders bet on price rises but were caught ...
Allstate reported a strong second quarter, signaling that its business turnaround is complete. The company’s premium growth remains cautious due to conservative underwriting, but both its Auto and Homeowners insurance lines are highly profitable, mai...
The Sky ecosystem plans a Nov. 19 upgrade to connect Osero’s liquidity layer on Ethereum and Base, enabling cross-chain USDC transfers. The upgrade activates Circle’s Cross-Chain Transfer Protocol on both networks, sets transfer limits, and adds a Ga...
Blockstream Research's recent paper identifies Falcon-1024 as the leading lattice-based signature scheme for quantum-proofing Bitcoin due to its compact size and efficient verification. However, significant hurdles remain, including high memory deman...
Arcutis Biotherapeutics awarded 58,500 restricted stock units and options for 17,000 shares to six new employees as an inducement to join the company. The grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with specific sched...
